 |
 |

Use of Nonprescription Weight Loss Products
Results From a Multistate Survey
Heidi Michels Blanck, PhD;
Laura Kettel Khan, PhD;
Mary K. Serdula, MD
JAMA. 2001;286:930-935.
Context Lifestyle changes to lose weight can be difficult; hence, both prescription and nonprescription diet products are appealing. Usage patterns of the nonprescription products phenylpropanolamine (PPA) and ephedra are of particular interest because of recent safety concerns.
Objective To estimate the prevalence of overall and specific nonprescription weight loss product use by demographic characteristics, prescription diet pill use, diabetic status, and lifestyle choices.
Design and Setting The Behavioral Risk Factor Surveillance System, a random-digit telephone survey conducted in 1998 in 5 states: Florida, Iowa, Michigan, West Virginia, and Wisconsin.
Participants Population-based sample of 14 679 noninstitutionalized adults 18 years or older.
Main Outcome Measures Prevalence of nonprescription weight loss product use in 1996-1998.
Results Seven percent reported overall nonprescription weight loss product use, 2% reported PPA use, and 1% reported ephedra product use. Overall use was especially common among young obese women (28.4%). Moreover, 7.9% of normal-weight women reported use. There was no difference in nonprescription weight loss product use by daily consumption of fruits and vegetables; however, more users than nonusers reported being physically active (for those who exercised 30 minutes 5 times per week, odds ratio, 1.5; 95% confidence interval, 1.2-2.0). Among prescription weight loss product users, 33.8% also took nonprescription product.
Conclusions With increasing rates of obesity, nonprescription product use is likely to increase. Clinicians should know about their patients' use of both prescription and nonprescription weight loss products.
Author Affiliations: Division of Nutrition and Physical Activity, National Center for Chronic Disease Prevention and Health Promotion (Drs Blanck, Khan, and Serdula), and Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office (Dr Blanck), Centers for Disease Control and Prevention, Atlanta, Ga.
RELATED ARTICLE
August 22/29, 2001
JAMA. 2001;286(8):977-978.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Use of a Prescribed Ephedrine/Caffeine Combination and the Risk of Serious Cardiovascular Events: A Registry-based Case-Crossover Study
Hallas et al.
Am J Epidemiol 2008;168:966-973.
ABSTRACT
| FULL TEXT
Developing a consumer evaluation tool of weight control strategy advertisements on the Internet
Luevorasirikul et al.
Health Educ Res 2008;23:567-575.
ABSTRACT
| FULL TEXT
Consumption of Dietary Supplements Containing Citrus aurantium (Bitter Orange)--2004 California Behavioral Risk Factor Surveillance Survey (BRFSS)
Klontz et al.
The Annals of Pharmacotherapy 2006;40:1747-1751.
ABSTRACT
| FULL TEXT
Weighing both sides: morality, mortality, and framing contests over obesity.
Saguy and Riley
Journal of Health Politics, Policy and Law 2005;30:869-921.
ABSTRACT
More Evidence Supporting the Ban of Ephedra Dietary Supplements
Chavez
The Annals of Pharmacotherapy 2004;38:895-897.
FULL TEXT
Physicians' Personal Intake and Prescription of Weight Loss Products: Are We Practicing What We Preach?
La Puma et al.
Arch Intern Med 2004;164:806-807.
FULL TEXT
Dietary supplements for body-weight reduction: a systematic review
Pittler and Ernst
Am. J. Clin. Nutr. 2004;79:529-536.
ABSTRACT
| FULL TEXT
Correlates of Weight Loss Behaviors Among Low-Income African-American, Caucasian, and Latina Women
Breitkopf and Berenson
Obstet Gynecol 2004;103:231-239.
ABSTRACT
| FULL TEXT
Ephedrine-Type Alkaloid-Containing Dietary Supplements and Substance Dependence
Miller and Waite
Psychosomatics 2003;44:508-511.
FULL TEXT
Anaphylactic Reaction to a Dietary Supplement Containing Willow Bark
Boullata et al.
The Annals of Pharmacotherapy 2003;37:832-835.
ABSTRACT
| FULL TEXT
Increasing the Amount of Fat in a Conjugated Linoleic Acid-Supplemented Diet Reduces Lipodystrophy in Mice
Tsuboyama-Kasaoka et al.
J. Nutr. 2003;133:1793-1799.
ABSTRACT
| FULL TEXT
Dietary Supplement Use by American Women: Challenges in Assessing Patterns of Use, Motives and Costs
Neuhouser
J. Nutr. 2003;133:1992S-1996.
ABSTRACT
| FULL TEXT
Health Risks of Selected Performance-Enhancing Drugs
Chyka
Journal of Pharmacy Practice 2003;16:37-44.
ABSTRACT
Update in Women's Health
Freund et al.
ANN INTERN MED 2003;138:119-127.
FULL TEXT
Use of Ephedra-containing products and risk for hemorrhagic stroke
Morgenstern et al.
Neurology 2003;60:132-135.
ABSTRACT
| FULL TEXT
Treatment With Dietary trans10cis12 Conjugated Linoleic Acid Causes Isomer-Specific Insulin Resistance in Obese Men With the Metabolic Syndrome
Riserus et al.
Diabetes Care 2002;25:1516-1521.
ABSTRACT
| FULL TEXT
Weight Loss Practices Among Malaysian Adults
Kong et al.
Asia Pac J Public Health 2002;14:99-104.
ABSTRACT
What Are Your Patients Taking to Lose Weight?
JWatch Women's Health 2001;2001:3-3.
FULL TEXT
Nonprescription Weight-Loss Product Use: Common and Potentially Dangerous
JWatch General 2001;2001:4-4.
FULL TEXT
|